Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cronos Group Inc (CRON) vs Rocket Lab USA Inc (RKLB) Price & Performance

Cronos Group IncTrade
Rocket Lab USA IncTrade

Price performance (Past 24H)

Key statistics

Cronos Group Inc vs Rocket Lab USA Inc — how do they compare? Cronos Group Inc trades at $3.08 (market cap $1.14B), while Rocket Lab USA Inc trades at $79.55 (market cap $50.01B). The key difference: Rocket Lab USA Inc is far larger — about 43.9× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals.

CRONRKLB
Market Cap
$1.14B$50.01B
Sector
HealthTechnology
52-Week High
$3.27$150.23
52-Week Low
$2.30$39.48
Enterprise Value
$341.13M$47.84B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cronos Group Inc

CRON trades at $3.165, up 5.5% with bullish technical signals from moving averages. The company shows strong revenue growth, with Q2 2026 beating expectations with $0.09 EPS versus $0.01 expected, and record quarterly performance. However, profitability remains inconsistent with negative net income in 2025. Analyst sentiment is mixed with 60% hold ratings, reflecting cautious optimism amid competitive pressures.

Outlook is cautiously optimistic with international expansion driving growth, but execution risks and cannabis sector volatility persist. The stock offers growth potential through European market penetration and product innovation, though investors should monitor margin improvements and competitive dynamics closely.

Rocket Lab USA Inc

Rocket Lab (RKLB) trades at $81.30, up 1.57% in the last session, with a bullish technical outlook and strong analyst support. The stock is near its pivot point of $79, with resistance at $82. Fundamentally, revenue grew 62% year-over-year in Q2 2026 to a record $601.80 million, but the company remains unprofitable with a net income margin of -26.87%. Recent news highlights the Neutron rocket's upcoming launch and a $2.36 billion backlog, though margin pressures and cash burn are concerns.

The outlook is mixed: analysts project 76% buy ratings and a $118.00 price target, signaling confidence in growth from launch demand and contracts. However, high valuation (P/S of 60.8), persistent losses, and execution risks around Neutron's timeline pose significant downside. Investors should weigh growth potential against profitability challenges and competitive pressures in the space sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cronos Group Inc

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.

Read more on CRON

About Rocket Lab USA Inc

Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.

Read more on RKLB